The New Frontier of Immuno-Oncology
Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
About Pionyr Immunotherapeutics
The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.
Our Science
Pionyr’s Myeloid TuningTM technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.
Pionyr Pipeline
Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials.
Become a Pionyr
Pionyr Immunotherapeutics is currently seeking individuals with myeloid biology, immunology, assay development, in vivo pharmacology, DMPK, or translational science expertise to help advance our lead programs into clinical testing.
Upcoming Events
June 15-16, 2022
Tumor Myeloid-Directed Therapies Summit, Boston, MA
Pionyr Presentation
Recent News
May 26, 2022
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022
May 3, 2022
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
March 22, 2022
Pionyr Immunotherapeutics Presents on Third Myeloid-Directed Therapeutic Program at Keystone Symposium
March 8, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
June 22, 2021
Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients
March 29, 2021
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
Contact Us
Pionyr Immunotherapeutics Inc.
2 Tower Pl, Suite 800
South San Francisco, CA 94080
(650) 825-6140
info@pionyrtx.com
